CYTK

Cytokinetics, Incorporated (CYTK) | Rumor.io

Cytokinetics

CYTK

Attention (50-day avg)0%

Attention rank (50-day avg)#932

Bullish sentiment (50-day avg)60%

Price to earnings ratio-10.1

Market capitalization9.2B

Earnings per share-7.22

Dividend yield (TTM)—

Revenue (annual)88M

Net income (annual)-785M

Social

What share of all stock conversation is about CYTK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% 0	0.01% +0.01

Aug 28

Cytokinetics, Incorporated ($CYTK) announced positive results from the ACACIA-HCM trial, showing a significant improvement in exercise capacity and patient-reported health status for patients with symptomatic nonobstructive hypertrophic cardiomyopathy.
The trial data was presented at the European Society of Cardiology (ESC) Congress 2026 and published in The New England Journal of Medicine, with the company's lead drug, aficamten, demonstrating a 53% improvement in meaningful outcomes versus a 13% improvement with placebo.
The results are significant for the company, which is preparing to submit a new drug application (NDA) to the FDA, with the presentation of the full results at the ESC Congress highlighting the potential for aficamten to address an unmet need in the treatment of non-obstructive HCM.

Generated by AI

Sentiment

Of the messages about CYTK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	10.17% -83.58	48.72% -43.45	78.16% +14.2
Bearish	—	89.83% +83.58	51.28% +43.45	21.84% -14.2

Bullish· Jun 29

$CYTK has been upgraded to Buy from Neutral by UBS with a price target of $115, driven by strong Myqorzo launch momentum and higher peak sales estimates.
The company is well-positioned for upside, with physician surveys indicating strong enthusiasm for Myqorzo adoption in obstructive hypertrophic cardiomyopathy (oHCM) and non-obstructive hypertrophic cardiomyopathy (nHCM).
The stock has broken into new territory, with a potential for more upside if it clears recent highs, and is being watched closely by big-pharma companies, including $NVS, which was previously in discussions to acquire Cytokinetics.

Bearish· May 5

$CYTK's biotech risk reversals are a scam trade, indicating a lack of fundamental value.
CYTK's recent data release showed lower-than-expected magnitude, but also significant losses and high burn rates, raising concerns about the company's commercial ramp and valuation.
CYTK's high debt levels and potential upcoming offering may lead to a significant drop in the stock price, making it a potentially shortable asset.

Generated by AI

Topics

Of the messages about CYTK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	90.48%	1.67%
Analysts	—	0%	0.68%	48.97%
Technical Analysis	—	100%	4.76%	0.05%
Earnings	—	0%	0%	0.07%
Controversies	—	0%	4.08%	0.08%
Macro	—	0%	0%	49.17%

Earnings· Nov 1

Cytokinetics, Incorporated ($CYTK) reported a loss of $0.40 per share, beating the estimated loss of $0.53 per share.
The company's Q3 revenue was $10.64 million, exceeding the estimated revenue by $7.88 million.
The Estimize Consensus for $CYTK's Q3 earnings was a loss of $0.01 per share and revenue of $0.54 million, which the company beat.

Announcements· May 5

Cytokinetics, Incorporated (CYTK) announced positive topline results from the ACACIA-HCM pivotal Phase 3 clinical trial of Aficamten in patients with non-obstructive hypertrophic cardiomyopathy.
The company reported $4.8 million in net product revenue from the U.S. launch of MYQORZO in approximately 9 weeks, and approximately $1.1 billion in cash, cash equivalents, and investments as of March 31, 2026.
Cytokinetics also announced a proposed public offering of common stock and a secondary offering of $650 million, with the company's cash, cash equivalents, and investments declining by approximately $144 million in Q1 2026.

Technical Analysis· Jul 19

$CYTK is expected to continue down after a short covering bounce, with a potential target at $25.
The stock is showing signs of a possible breakout, with a squeeze in its Ascending Triangle Pattern and a potential move to $30.
$CYTK has failed to hold support at $30 and $29, and longs may want to take profits while they can, with a potential re-entry closer to $22-24.

Generated by AI

Community

Of the messages about CYTK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.54%	92.36%	12.39%
Newcomers	0%	1.46%	7.64%	87.61%

Regulars· Aug 28

Cytokinetics, Incorporated's aficamten has shown significant improvements in patient quality-of-life scores and exercise capacity versus placebo in patients with non-obstructive hypertrophic cardiomyopathy.
The company's ACACIA-HCM trial has met both dual primary endpoints, with aficamten demonstrating robust efficacy and manageable safety in non-obstructive HCM, with a planned FDA submission.
The market's reaction to the positive trial results has been overly negative, with some investors seeing the stock as a "buy the dip" opportunity.

Newcomers· Jun 27

I've been reading about Cytokinetics, Incorporated and I'm excited to learn more about their efforts in developing treatments for heart failure and other conditions.
I'm following the progress of Cytokinetics, Incorporated and I'm intrigued by the potential of their small molecule drugs to improve muscle function.
Cytokinetics, Incorporated's focus on muscle biology has caught my attention, and I'm curious to see how their research will impact the treatment of diseases like heart failure.

Generated by AI

Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure. Isaac Ciecha

4d agoYahoo Finance

Cytokinetics at bernstein healthcare forum: push beyond first launch

6d agoInvesting.com

Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

6d agoYahoo Finance

Cytokinetics EVP Fady Malik sells $239k in company stock

7d agoInvesting.com

Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years - Cytokinetics (NASDAQ

Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 15 years by 2.64% on an annualized basis producing an average annual return of 15.99%. Currently, Cytokinetics has a market capitalization of $9.70

8d agoBenzinga

Also Discussed

Investors talking about CYTK also mention

#	Name	Attention
1	SWTX - SpringWorks Therapeutics, Inc.	——
2	Edgewise Therapeutics Inc.EWTX	0%new
3	MRTX - Mirati Therapeutics, Inc.	——
4	Arcus Biosciences, Inc.RCUS	0%new
5	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
6	Abivax SAABVX	0.01%-0.01
7	BPMC - Blueprint Medicines Corporation	——
8	DAWN - Day One Biopharmaceuticals, Inc.	——
9	Mineralys Therapeutics, Inc.MLYS	0%+0
10	FOLD - Amicus Therapeutics, Inc.	——

Cytokinetics, Incorporated

Healthcare
Biotechnology

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised. The company markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, and is advancing additional drug candidates such as aficamten for broader hypertrophic cardiomyopathy use and omecamtiv mecarbil for heart failure. Cytokinetics also develops other muscle-directed candidates in clinical-stage programs, reflecting its emphasis on precision treatments for diseases affecting cardiac and skeletal muscle function. Headquartered in South San Francisco, California, Cytokinetics plays a specialized role in the biopharmaceutical market by focusing on muscle performance disorders within cardiovascular medicine.

Website

Location

350 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about CYTK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% 0	0.01% +0.01

Aug 28

Cytokinetics, Incorporated ($CYTK) announced positive results from the ACACIA-HCM trial, showing a significant improvement in exercise capacity and patient-reported health status for patients with symptomatic nonobstructive hypertrophic cardiomyopathy.
The trial data was presented at the European Society of Cardiology (ESC) Congress 2026 and published in The New England Journal of Medicine, with the company's lead drug, aficamten, demonstrating a 53% improvement in meaningful outcomes versus a 13% improvement with placebo.
The results are significant for the company, which is preparing to submit a new drug application (NDA) to the FDA, with the presentation of the full results at the ESC Congress highlighting the potential for aficamten to address an unmet need in the treatment of non-obstructive HCM.

Generated by AI

Sentiment

Of the messages about CYTK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	10.17% -83.58	48.72% -43.45	78.16% +14.2
Bearish	—	89.83% +83.58	51.28% +43.45	21.84% -14.2

Bullish· Jun 29

$CYTK has been upgraded to Buy from Neutral by UBS with a price target of $115, driven by strong Myqorzo launch momentum and higher peak sales estimates.
The company is well-positioned for upside, with physician surveys indicating strong enthusiasm for Myqorzo adoption in obstructive hypertrophic cardiomyopathy (oHCM) and non-obstructive hypertrophic cardiomyopathy (nHCM).
The stock has broken into new territory, with a potential for more upside if it clears recent highs, and is being watched closely by big-pharma companies, including $NVS, which was previously in discussions to acquire Cytokinetics.

Bearish· May 5

$CYTK's biotech risk reversals are a scam trade, indicating a lack of fundamental value.
CYTK's recent data release showed lower-than-expected magnitude, but also significant losses and high burn rates, raising concerns about the company's commercial ramp and valuation.
CYTK's high debt levels and potential upcoming offering may lead to a significant drop in the stock price, making it a potentially shortable asset.

Generated by AI

Topics

Of the messages about CYTK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	90.48%	1.67%
Analysts	—	0%	0.68%	48.97%
Technical Analysis	—	100%	4.76%	0.05%
Earnings	—	0%	0%	0.07%
Controversies	—	0%	4.08%	0.08%
Macro	—	0%	0%	49.17%

Earnings· Nov 1

Cytokinetics, Incorporated ($CYTK) reported a loss of $0.40 per share, beating the estimated loss of $0.53 per share.
The company's Q3 revenue was $10.64 million, exceeding the estimated revenue by $7.88 million.
The Estimize Consensus for $CYTK's Q3 earnings was a loss of $0.01 per share and revenue of $0.54 million, which the company beat.

Announcements· May 5

Cytokinetics, Incorporated (CYTK) announced positive topline results from the ACACIA-HCM pivotal Phase 3 clinical trial of Aficamten in patients with non-obstructive hypertrophic cardiomyopathy.
The company reported $4.8 million in net product revenue from the U.S. launch of MYQORZO in approximately 9 weeks, and approximately $1.1 billion in cash, cash equivalents, and investments as of March 31, 2026.
Cytokinetics also announced a proposed public offering of common stock and a secondary offering of $650 million, with the company's cash, cash equivalents, and investments declining by approximately $144 million in Q1 2026.

Technical Analysis· Jul 19

$CYTK is expected to continue down after a short covering bounce, with a potential target at $25.
The stock is showing signs of a possible breakout, with a squeeze in its Ascending Triangle Pattern and a potential move to $30.
$CYTK has failed to hold support at $30 and $29, and longs may want to take profits while they can, with a potential re-entry closer to $22-24.

Generated by AI

Community

Of the messages about CYTK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	98.54%	92.36%	12.39%
Newcomers	0%	1.46%	7.64%	87.61%

Regulars· Aug 28

Cytokinetics, Incorporated's aficamten has shown significant improvements in patient quality-of-life scores and exercise capacity versus placebo in patients with non-obstructive hypertrophic cardiomyopathy.
The company's ACACIA-HCM trial has met both dual primary endpoints, with aficamten demonstrating robust efficacy and manageable safety in non-obstructive HCM, with a planned FDA submission.
The market's reaction to the positive trial results has been overly negative, with some investors seeing the stock as a "buy the dip" opportunity.

Newcomers· Jun 27

I've been reading about Cytokinetics, Incorporated and I'm excited to learn more about their efforts in developing treatments for heart failure and other conditions.
I'm following the progress of Cytokinetics, Incorporated and I'm intrigued by the potential of their small molecule drugs to improve muscle function.
Cytokinetics, Incorporated's focus on muscle biology has caught my attention, and I'm curious to see how their research will impact the treatment of diseases like heart failure.

Generated by AI

Cytokinetics

Social

Aug 28

Bullish· Jun 29

Bearish· May 5

Earnings· Nov 1

Announcements· May 5

Technical Analysis· Jul 19

Regulars· Aug 28

Newcomers· Jun 27

Cytokinetics CEO Robert Blum sells $490,949 in stock

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Cytokinetics at bernstein healthcare forum: push beyond first launch

Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Cytokinetics EVP Fady Malik sells $239k in company stock

Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years - Cytokinetics (NASDAQ

Also Discussed

Cytokinetics, Incorporated

Company Information

Location

Cytokinetics CEO Robert Blum sells $490,949 in stock

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Cytokinetics at bernstein healthcare forum: push beyond first launch

Cytokinetics (CYTK): Can Myqorzo Growth Create a New Biopharma Success Story?

Cytokinetics EVP Fady Malik sells $239k in company stock

Here’s How Much You Would Have Made Owning Cytokinetics Stock In The Last 15 Years - Cytokinetics (NASDAQ

Also Discussed

Social

Aug 28

Bullish· Jun 29

Bearish· May 5

Earnings· Nov 1

Announcements· May 5

Technical Analysis· Jul 19

Regulars· Aug 28

Newcomers· Jun 27